HUE027537T2 - Szemcsés készítmények gyengén oldódó hatóanyagok bevitelére - Google Patents

Szemcsés készítmények gyengén oldódó hatóanyagok bevitelére Download PDF

Info

Publication number
HUE027537T2
HUE027537T2 HUE08829074A HUE08829074A HUE027537T2 HU E027537 T2 HUE027537 T2 HU E027537T2 HU E08829074 A HUE08829074 A HU E08829074A HU E08829074 A HUE08829074 A HU E08829074A HU E027537 T2 HUE027537 T2 HU E027537T2
Authority
HU
Hungary
Prior art keywords
pharmaceutical compositions
compositions
peg
composition
poorly soluble
Prior art date
Application number
HUE08829074A
Other languages
English (en)
Inventor
James D Talton
Original Assignee
Nanotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanotherapeutics Inc filed Critical Nanotherapeutics Inc
Publication of HUE027537T2 publication Critical patent/HUE027537T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Claims (5)

  1. Âgitméiïplï gyeoglh tfÉ^&ÉSaayagpfc bevitelére Szabadalm i i gènypontok 1, iiompozfeió, amely 2 mm-nil kisebb átlagos átmérőjű szemeseket tartalmaz, ahol a részecskék bnpmaortmt vagy büprénötfk HCI-t tdrtalibMbak kh.
  2. #.2 » kh ê % Éfcésnyiségben a szemcsék tömegére vonatkoztatva, valamint pöietim-ghkok (PEG), ahoi a buprenorfín vagy bnprcnörihiïGI a PEG által bekapszulázott. 2*. Az 1 - Igénypont szerinti kompozíció, ahol a PEU átlagos molekulatömegéi a kb,: !ü Dalion - ki, 10000 Dalion tatíoptányba esik, vagy ahol a EEG a PEG 3350.
  3. 3. Az 1, igénypont szerinti kompozíció:, amely továbbá egy felületaktív anyagot tártál-máz.
  4. 4. Gyógyászati készítmény* amely az 1, igénypont szerinti kompozíciót és naiokorit tartalmaz.
  5. 5. A 4, igénypont szerinti gyógyászai készítmény, tárni a iompozlem orális beadásra kialakított.
HUE08829074A 2007-09-03 2008-09-02 Szemcsés készítmények gyengén oldódó hatóanyagok bevitelére HUE027537T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US96967207P 2007-09-03 2007-09-03

Publications (1)

Publication Number Publication Date
HUE027537T2 true HUE027537T2 (hu) 2016-10-28

Family

ID=40377549

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE08829074A HUE027537T2 (hu) 2007-09-03 2008-09-02 Szemcsés készítmények gyengén oldódó hatóanyagok bevitelére

Country Status (14)

Country Link
US (3) US8377479B2 (hu)
EP (2) EP2197429B9 (hu)
JP (1) JP2010537989A (hu)
KR (1) KR101545874B1 (hu)
AU (1) AU2008296971B2 (hu)
CA (1) CA2699172C (hu)
DK (1) DK2197429T3 (hu)
ES (1) ES2572157T3 (hu)
HK (1) HK1226306A1 (hu)
HU (1) HUE027537T2 (hu)
MX (1) MX2010002409A (hu)
PL (1) PL2197429T3 (hu)
SI (1) SI2197429T1 (hu)
WO (1) WO2009032246A2 (hu)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04003597A (es) * 2001-10-18 2004-07-30 Nektar Therapeutics Al Corp Conjugados polimericos de antagonistas opiaceos.
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
MX354603B (es) 2007-05-25 2018-03-13 Indivior Uk Ltd Formulaciones de transferencia sostenida de compuestos de risperidona.
EP2197429B9 (en) * 2007-09-03 2016-10-26 Nanotherapeutics, Inc. Particulate compositions for delivery of poorly soluble drugs
AU2010206724A1 (en) * 2009-01-22 2011-07-28 Nanotherapeutics, Inc. Process for preparing particles of opioids and compositions produced thereby
US20100273730A1 (en) * 2009-04-27 2010-10-28 Innopharmax, Inc. Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof
US9125867B2 (en) * 2010-02-24 2015-09-08 Invincible Biotechnology Diversion- and/or abuse-resistant compositions and methods for making the same
GB2513060B (en) * 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
SI2616064T1 (sl) 2010-10-21 2019-12-31 Rtu Pharmaceuticals Llc Pripravki ketorolaka, pripravljeni za uporabo
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
EP3169315B1 (en) 2014-07-17 2020-06-24 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
CA2964628A1 (en) * 2014-10-20 2016-04-28 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
JP6797115B2 (ja) 2014-11-04 2020-12-09 イノファーマックス インコーポレイテッド 不安定または吸収不良薬物の経口投与
US11000520B2 (en) 2014-11-07 2021-05-11 Indivior Uk Limited Buprenorphine dosing regimens
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
WO2019064026A1 (en) 2017-09-29 2019-04-04 Orexo Ab NEW PHARMACEUTICAL COMPOSITIONS
GB201904767D0 (en) 2019-04-04 2019-05-22 Orexo Ab New pharmaceutical compositions

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA987588A (en) * 1970-01-02 1976-04-20 Sidney Riegelman Solid dispersions of drugs
DE2400819C2 (de) * 1974-01-09 1982-04-22 Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung fester Zubereitungen von schwerlöslichen Arzneimittelwirkstoffen in feinster Verteilung
US4722941A (en) * 1978-06-07 1988-02-02 Kali-Chemie Pharma Gmbh Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof
ATE5852T1 (de) 1978-11-20 1984-02-15 American Home Products Corporation Therapeutische zusammensetzungen mit gesteigerter bioverfuegbarkeit und verfahren zu deren herstellung.
US4525339A (en) * 1982-10-15 1985-06-25 Hoffmann-La Roche Inc. Enteric coated oral dosage form
JPS6163614A (ja) * 1984-09-04 1986-04-01 Yamanouchi Pharmaceut Co Ltd 難溶性薬物の溶解速度向上方法
GB8514665D0 (en) * 1985-06-11 1985-07-10 Eroceltique Sa Oral pharmaceutical composition
US5190748A (en) * 1988-11-22 1993-03-02 Hoffmann-La Roche Inc. Absorption enhancement of antibiotics
AU7496991A (en) * 1990-03-20 1991-10-21 Otsuka Pharmaceutical Co., Ltd. Liposome preparation
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
FR2735658B1 (fr) * 1995-06-21 1997-09-12 Capsulis Encapsulation de composes a usage alimentaire par des tensioactifs
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US6235313B1 (en) * 1992-04-24 2001-05-22 Brown University Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
US5352459A (en) * 1992-12-16 1994-10-04 Sterling Winthrop Inc. Use of purified surface modifiers to prevent particle aggregation during sterilization
US5981719A (en) * 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5318781A (en) * 1993-04-06 1994-06-07 Hoffmann-La Roche Inc. Absorption enhancement of antibiotics
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
IE940292A1 (en) * 1994-04-06 1995-10-18 Elan Corp Plc Biodegradable microcapsules and method for their manufacture
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US6368586B1 (en) * 1996-01-26 2002-04-09 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers
AU2059297A (en) * 1996-03-12 1997-10-01 Alza Corporation Composition and dosage form comprising opioid antagonist
GB9606188D0 (en) * 1996-03-23 1996-05-29 Danbiosyst Uk Pollysaccharide microspheres for the pulmonary delivery of drugs
EP0811374A1 (en) * 1996-05-29 1997-12-10 Pfizer Inc. Combination dosage form comprising cetirizine and pseudoephedrine
US5858531A (en) * 1996-10-24 1999-01-12 Bio Syntech Method for preparation of polymer microparticles free of organic solvent traces
US5948787A (en) * 1997-02-28 1999-09-07 Alza Corporation Compositions containing opiate analgesics
CN1234362C (zh) 1997-12-22 2006-01-04 欧罗赛铁克股份有限公司 阿片样激动剂/阿片样拮抗剂组合物
TR200001828T2 (tr) 1997-12-22 2000-11-21 Euro-Celtique, S.A. Opioid dozaj şekillerinin kötüye kullanımını önlemeye yönelik bir yöntem.
FR2774910B1 (fr) * 1998-02-16 2001-09-07 Ethypharm Lab Prod Ethiques Microgranules de sulfate de morphine, procede de fabrication et preparations pharmaceutiques
US6190699B1 (en) * 1998-05-08 2001-02-20 Nzl Corporation Method of incorporating proteins or peptides into a matrix and administration thereof through mucosa
JP2000086509A (ja) * 1998-09-14 2000-03-28 Taisho Yakuhin Kogyo Kk ソファルコン含有製剤の製造方法
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US6733789B1 (en) * 1999-01-21 2004-05-11 Biovail Laboratories, Inc. Multiparticulate bisoprolol formulation
US6270806B1 (en) * 1999-03-03 2001-08-07 Elan Pharma International Limited Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions
US6223455B1 (en) * 1999-05-03 2001-05-01 Acusphere, Inc. Spray drying apparatus and methods of use
US6406745B1 (en) * 1999-06-07 2002-06-18 Nanosphere, Inc. Methods for coating particles and particles produced thereby
CZ2002728A3 (cs) * 1999-08-27 2002-08-14 Southern Research Institute Prostředek ve formě mikročástic obsahující buprenorfin, léková forma a pouľití
US6480524B1 (en) * 1999-09-13 2002-11-12 Nortel Networks Limited Multiple beam antenna
AR031682A1 (es) * 1999-11-19 2003-10-01 Reckitt Benckiser Helthcare Uk Composiciones farmaceuticas
EP2092936B1 (en) * 2000-02-08 2013-03-20 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
US6248360B1 (en) * 2000-06-21 2001-06-19 International Health Management Associates, Inc. Complexes to improve oral absorption of poorly absorbable antibiotics
PT1296651E (pt) * 2000-06-27 2008-02-12 Vectura Ltd Método para fazer partículas para serem usadas numa composição farmacêutica
KR100421139B1 (ko) * 2000-10-05 2004-03-04 삼성전자주식회사 시분할 듀플렉싱 부호분할다중접속 이동통신시스템을 위한타임 스위치드 전송 다이버시티 장치 및 방법
WO2002036099A1 (en) 2000-10-30 2002-05-10 Euro-Celtique S.A. Controlled release hydrocodone formulations
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
AU2003263024A1 (en) * 2002-04-23 2003-11-10 Christopher Mcconville Process of forming and modifying particles and compositions produced thereby
US7157102B1 (en) * 2002-05-31 2007-01-02 Biotek, Inc. Multi-layered microcapsules and method of preparing same
US20040110781A1 (en) * 2002-12-05 2004-06-10 Harmon Troy M. Pharmaceutical compositions containing indistinguishable drug components
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US20040191301A1 (en) * 2003-03-27 2004-09-30 Van Duren Albert Philip Transdermal device having a phase change material
EP1610763A2 (en) * 2003-03-31 2006-01-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem Stable liposomes or micelles comprising a sphingolipid and a peg-lipopolymer
US20050048115A1 (en) * 2003-08-27 2005-03-03 Murty Mangena Buprenorphine microspheres
IL159729A0 (en) * 2004-01-06 2004-06-20 Doron I Friedman Non-aqueous composition for oral delivery of insoluble bioactive agents
CA2552925A1 (en) * 2004-01-30 2005-08-18 Pfizer Italia S.R.L. Semisolid matrix pharmaceutical formulations
ES2246694B1 (es) * 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. Nanoparticulas pegiladas.
FR2878158B1 (fr) * 2004-11-24 2009-01-16 Flamel Technologies Sa Forme pharmaceutique orale, microparticulaire solide concue pour eviter le mesusage
JP2006232694A (ja) * 2005-02-23 2006-09-07 Univ Nihon 難溶性医薬とシクロデキストリン化合物からなる複合体及びその製造方法
WO2007003278A1 (en) * 2005-07-05 2007-01-11 Abbott-Gmbh & Co. Kg Composition and dosage form comprising a solid or semi-solid matrix
US8074906B2 (en) 2005-07-07 2011-12-13 Nanotherapeutics, Inc. Process for milling and preparing powders and compositions produced thereby
US20070020339A1 (en) * 2005-07-20 2007-01-25 Pharmorx Inc. Compositions and methods for controlling abuse of medications
EP2197429B9 (en) * 2007-09-03 2016-10-26 Nanotherapeutics, Inc. Particulate compositions for delivery of poorly soluble drugs

Also Published As

Publication number Publication date
AU2008296971A1 (en) 2009-03-12
JP2010537989A (ja) 2010-12-09
EP2197429B1 (en) 2016-04-20
EP3064198A1 (en) 2016-09-07
US20090061011A1 (en) 2009-03-05
DK2197429T3 (en) 2016-05-30
PL2197429T3 (pl) 2016-09-30
US9554996B2 (en) 2017-01-31
CA2699172C (en) 2016-05-17
AU2008296971B2 (en) 2014-10-02
US20130129828A1 (en) 2013-05-23
WO2009032246A3 (en) 2009-04-23
HK1226306A1 (zh) 2017-09-29
KR101545874B1 (ko) 2015-08-20
US20170143698A1 (en) 2017-05-25
SI2197429T1 (sl) 2016-09-30
US8377479B2 (en) 2013-02-19
ES2572157T3 (es) 2016-05-30
EP2197429A2 (en) 2010-06-23
EP2197429B9 (en) 2016-10-26
KR20100063106A (ko) 2010-06-10
WO2009032246A2 (en) 2009-03-12
MX2010002409A (es) 2010-05-19
CA2699172A1 (en) 2009-03-12

Similar Documents

Publication Publication Date Title
DK2197429T3 (en) Particulate compositions for delivery of poorly soluble drugs
EP2836197B1 (en) Oral film containing opiate enteric-release beads
US10300142B2 (en) Compositions with a rheological modifier to reduce dissolution variability
US20160051535A1 (en) Morphinan Derivatives for the Treatment of Drug Overdose
KR20090038447A (ko) 다층 경구 붕해 정제
KR20110122775A (ko) 내변조성 제형
PT1615615E (pt) Produtos invioláveis para administração de opióides
CN103415285A (zh) 包含阿片样激动剂和被隔离的拮抗剂的药物组合物
US20100183687A1 (en) Process for preparing particles of opioids and compositions produced thereby
WO2015086528A1 (de) Naloxon-monopräparat und mehrschichttablette
AU2014277657B2 (en) Particulate Compositions for Delivery of Poorly Soluble Drugs
AU2016266061A1 (en) Particulate Compositions for Delivery of Poorly Soluble Drugs
US20160256451A1 (en) Dosage of naloxone
CA3071261A1 (en) Oral tablet formulations